Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)

NCT01981850 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01981850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01981850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2013
Completion date
July 10, 2020
Enrollment
125 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera, post-essential thrombocythemia myelofibrosis, primary myelofibrosis